CAS NO: | 879085-55-9 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
1 g | 电议 |
生物活性 | Vismodegib (GDC-0449) is an orally activehedgehogpathway inhibitor with anIC50of 3 nM. Vismodegib also inhibitsP-gp,ABCG2with IC50values of 3.0 μM and 1.4 μM, respectively[1][2]. | ||||||||||||||||
IC50& Target | IC50: 3 nM (hedgehog), 3.0 μM (P-gp), 1.4 μM (ABCG2)[1][2] | ||||||||||||||||
体外研究 (In Vitro) | Vismodegib (HhAntag691) is an ABCG2 inhibitor and can increase the effective intracellular concentration of NSC 279836, another ABCG2 substrate, through blocking its export in HEK293 cells. Vismodegib (HhAntag691, 10 μM), resensitizes MDCKII/Pgp cells and MDCKII/MRP1 cells to NSC757 treatment[2]. Vismodegib (25 μM or 50 μM) concentration dependently inhibits HCC and H1339 cells[3]. | ||||||||||||||||
体内研究 (In Vivo) | Vismodegib is a novel small molecule HPI, often used for clinical trials[1]. Vismodegib (0.3 to 75 mg/kg, p.o.) is highly efficacious in medulloblastoma allograft tumors. Vismodegib (>46 mg/kg, p.o.) causes growth delay in patient-derived colorectal xenografts[4]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 421.30 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C19H14Cl2N2O3S | ||||||||||||||||
CAS 号 | 879085-55-9 | ||||||||||||||||
中文名称 | 维莫德吉 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(118.68 mM;Need ultrasonic) Ethanol : 3.33 mg/mL(7.90 mM;ultrasonic and warming and heat to 60℃) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|